Drug Discovery

Why the ability to design therapeutics based on glycobiology will make a mark on pharma R&D.

Why scientists are looking to the microscopic marvel of the tardigrade for new approaches to cancer treatment.

Experts explain why these are two important areas to watch in the near future of pharma R&D.

Purdue University’s Young Institute is tackling pharma’s toughest challenges— from mRNA stability to aseptic manufacturing.

We get the story behind the development of Spiroligomer molecules and how they can help drug the undruggable.

How antisense oligonucleotides open up targeted approaches to rare disease treatment.

Researchers develop a new platform to improve delivery of oligonucleotide therapies to muscle.

Why researchers are excited about the potential of extracellular vesicles from umbilical cord-derived stem cells.

We asked three rare disease drug developers about their work, the challenges facing the field, and what they would do with unlimited funds.

Bluebird bio’s financial situation is a stark reminder of the challenges of developing advanced therapies for rare diseases.